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ABSTRACT

The expanded understanding of the gene families and mechanisms governing
tumorigenesis pathways has enormous potential for improving current cancer therapies
and patient prognoses. One such gene family that participates in the regulation of
tumorigenesis is the tumor necrosis factor alpha-induced protein 8 (TNFAIP8) gene
family, which is comprised of four members: TNFAIP8, TNFAIP8L1, TNFAIP8L2, and
TNFAIP8L3. The TNFAIP8L1 gene is thought to function as a tumor suppressor, but the
mechanisms by which it exerts this function have yet to be elucidated. We hypothesize
that the TNFAIP8L1 protein acts as a tumor suppressor through protein-protein
interactions that regulate tumor proliferation, migration, and/or angiogenesis. The H1299
non-small cell lung cancer cell line was engineered to overexpress TNFAIP8L1 protein
and is being used as an in vitro model to identify putative protein binding partners
through co-immunoprecipitation and mass spectrometry assays. Apparent interactions
will be validated by mammalian two-hybrid assays. We anticipated that TNFAIP8L1
would bind proteins involved in tumorigenesis pathways and that these may reveal new
avenues of study and hold important clinical relevance in current cancer treatment plans.
We identified 138 putative protein interactions involving TNFAIP8L1.

“Don't you know
They're talking about a revolution
It sounds like a whisper
And finally the tables are starting to turn
Talking about a revolution
Yes, finally the tables are starting to turn”
– Tracy Chapman

To everyone who is fighting to turn the tables.
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INTRODUCTION

Overview
Cancer is a devastating disease and one of the most clinically relevant illnesses of
our time. It was the second leading cause of death worldwide in 2015, claiming the lives
of 8.8 million people (World Health Organization, 2018). There are many burdens
associated with cancer to the individual, health care systems, and society at-large.
Approximately 40% of people will be diagnosed with cancer in their lifetime, resulting in
171.2 deaths per 100,000 people each year (World Health Organization, 2018). The
leading cause of cancer deaths is lung cancer, which accounts for 25% of all cancer
deaths. This is more than colon, breast, and prostate cancer combined (American Cancer
Society, 2018). Despite these overwhelming statistics, there is no cure for cancer.
There are numerous clinical approaches to treat cancer, but they are not flawless
and leave room for improvement. In the 1960’s cancer treatments and therapies were
beginning to be researched and integrative approaches were implemented. During the
period from 1974 to 1976, the 5-year relative survival rate for all cancers combined was
50% for adults and 62% for children (National Institute of Health, 2013). Current
techniques combine elements of medicine and lifestyle changes. A few of the most
common medical interventions are chemotherapy, radiotherapy, and surgery.
Chemotherapy uses drugs to kill cancer cells, usually through pills, intravenous access, or
injection. It is commonly used in conjunction with other therapies like radiotherapy or
surgery. Radiotherapy uses high doses of radiation to kill cancer and shrink tumors
(National Cancer Institute, 2017). With the advances in technology, and evidence-based
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research, there has been an increase in survival rates for adults and children diagnosed
with cancer. As of 2006, the 5-year survival rates of adults and children diagnosed with
cancer had increased to 68% and 81%, respectively (National Institute of Health, 2013).
As improved understanding of the mechanisms behind tumorigenesis and
technological advances occur, the survival numbers should continue to increase. The
importance of regular physician visits for screening, diagnosis, therapies, and treatment
are crucial, but it is beneficial to also consider the importance of prevention. Important
factors for prevention include diet choice, exercise, and environmental exposure to
carcinogens. In regard to diet, the American Cancer Society recommends that the amount
of red meat and processed meat ingested, as well as the number of alcoholic beverages
consumed, be limited. It is also beneficial to eat adequate amounts of fruits and
vegetables, as well as switching from refined to whole grains. Adults should engage in
moderate intensity physical activity for at least 2.5 hrs per week, and children should get
1 hr of moderate intensity physical activity per day (American Cancer Society, 2016).
Other things to consider are vaccinations against oncogenic viruses like human
papillomavirus, as well as limiting exposure to cigarette smoke and ultraviolet radiation
(Center for Disease Control and Prevention, 2018).
There are numerous causes of cancer, but most exhibit these six hallmarks of
acquired biological capabilities: evading apoptosis, self-sufficiency in growth signals,
insensitivity to anti-growth signals, sustained angiogenesis, limitless replicative potential,
and the ability to invade tissues and metastasize (Figure 1) (D Hanahan & Weinberg,
2000). Though this view reduces a complex group of diseases down to a few common
features, it can be helpful to initially study cellular processes in a microcosm. However, it
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should also be mentioned that a systems biology approach would be beneficial to
understanding disease processes since the processes in nature do not exist in a microcosm
(Fang & Casadevall, 2011).

Figure 1. The six hallmarks of cancer shown as acquired capabilities of cells
(Douglas Hanahan & Weinberg, 2011). Cell, Volume 144, Issue 5 , Douglas
Hanahan,Robert A. Weinberg, Hallmarks of Cancer: The Next Generation, Pages
646-672, Copyright (2011), with permission (4339050057477) from Elsevier.
Regulation of these processes occurs through many different gene families and
proteins at work, including the tumor necrosis factor alpha- induced protein 8
(TNFAIP8) gene family, a relatively new, yet significant family in the regulation of
inflammation, immunity, and cancer processes (Lou & Liu, 2011). The TNFAIP8 gene
family is comprised of four members: TNFAIP8, TNFAIP8L1, TNFAIP8L2, and
TNFAIP8L3 (Sullivan, Lage, Yoder, Postlethwait, & Kim, 2017). All four gene family
members encode for proteins that are thought to contain seven alpha helices, with a
hydrophobic cavity in the center. The cavity is thought to serve as a binding site for cofactors and molecules interacting with the protein, including lipid second messengers
3

required for signaling (Fayngerts et al., 2014; X. Zhang et al., 2009). TNFAIP8 and
TNFAIP8L2 are involved with immune regulation and inflammation, as well as the
development and regulation of cancers through roles as either tumor suppressors or tumor
promoters (Porturas et al., 2015; X. Zhang et al., 2009). The entire TNFAIP8 gene family
has been linked to cancers ranging from liver and lung cancer to blood and bone cancers
(Table 1). The TNFAIP8L1 gene is thought to function as a tumor suppressor, but the
mechanisms by which it exerts this function have yet to be elucidated, leaving potential
for improving current cancer therapies and patient prognoses with increased
understanding of the mechanisms (Z. Zhang et al., 2015) .
Gene

Function

TNFAIP8

Tumor
Promoter or
Tumor
Suppressor
Tumor
Suppressor
Tumor
Suppressor

TNFAIP8L1
TNFAIP8L2

TNFAIP8L3

Tumor
Promoter

Associated
Cancers
Stomach, Prostate,
Ovarian, Lung,
Blood, Bone
Liver, Lung
Stomach, Kidney,
Liver, Lung, Bone

Lung, Cervix,
Colon

References
(Chen et al., 2016; Cheng
et al., 2015; Eisele et al.,
2007; Liu et al., 2012;
Xing & Ren, 2016)
(Wu et al., 2017; Z.
Zhang et al., 2015)
(Cao et al., 2013; Deng,
Feng, & Deng, 2015; Y.
Li et al., 2015; Peng et
al., 2016; Zongliang
Zhang, Qi, Hou, & Jin,
2013)
(Fayngerts et al., 2014b)

Table 1. Cancer types previously associated with each gene in the TNFAIP8 gene family.

Cancer
Cancer is a group of diseases where cells in the body divide uncontrollably and
migrate into surrounding tissues (National Cancer Institute, 2015). It is characterized by
the six hallmarks of cancer (Figure 1)(D Hanahan & Weinberg, 2000). Cancer is a

4

disease that arises from changes in genes that control cellular functions such as the cell
cycle, cell metabolism and cell death. These genetic changes can occur due to many
environmental and lifestyle factors, as well as a number of unknown reasons. Behaviors
such as tobacco smoking, use of drugs and alcohol, as well as ultraviolet, and x-ray
radiation can increase the risk of cancer (National Cancer Institute, 2015). According to
the World Health Organization, dietary choices, including processed meat and red meat,
can also cause increased risks of cancer, especially colorectal cancer (Harvard School of
Public Health, 2015).
There are more than 100 types of cancer, ranging from the more common breast,
prostate, and lung cancers to more rare types such as fallopian tube or heart cancer
(National Cancer Institute, 2015). Cancer has a massive impact on individuals, families,
and societies across the globe. In 2012, there were 14 million new cases of cancer and 8.2
million cancer related deaths. In the United States alone, 1.68 million new cases of cancer
were estimated for 2016 (“Cancer Statistics - National Cancer Institute,” 2017). These
statistics place cancer as the second leading cause of death globally and there is currently
no cure, however, there are numerous treatment options with varying degrees of success
depending on cancer type (World Health Organization, 2018).
The devastation that cancer leaves in its wake is shown in the statistics above, but
it also takes a toll on the economy of nations, the health care system, and survivors. It is
estimated that the direct health care costs in the United States for cancer in 2015 reached
80.2 billion USD and the total economic cost including loss of productivity was 1.16
trillion USD in 2010 (American Cancer Society, World Health Organization 2018). With
the number of cases predicted to rise, the economic costs will also rise. The personal and
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societal problems associated with cancer are demonstrated in quality of life research
performed with the help of survivors. One study revealed that there were four major
domains of life that were altered for survivors including physical well-being,
psychological well-being, social well-being and spiritual well-being (Mollica, Nemeth,
Newman, & Mueller, 2015). The survivors noted decreased satisfaction in these areas of
their life. Physical well-being was marked by dissatisfaction in strength, fatigue pain, and
the ability to perform daily activities, while psychological well-being was marked by
issues of anxiety, depression, and fear of recurrence of cancer. The last two domains
focused on issues relating to hope, inner strength, religion, appearance, relationships, and
feelings of isolation (Mollica et al., 2015). As scientists, citizens, and humans, there
should be an emphasis placed on filling knowledge gaps surrounding cancer processes
and their regulations so that more effective prevention and treatment options can be
revealed.
It is also important to note that a disproportionately high number of cancer cases
due to preventable diseases such as human papillomavirus and cancer deaths occur in
low-income and middle-income countries, where prevention, diagnosis and treatment are
not affordable or available (World Health Organization, 2018). The best way to reduce
the burden of cancer is to avoid risk factors, vaccinate against cancer associated viruses,
and get regular screenings. Prevention and early detection are vital to decreasing cancer
burden (American Cancer Society, 2018a). There are several clinical approaches to treat
cancer, but they are not perfect and leave room for improvement in patient outcomes, cost
effectiveness, and specificity of treatment as outlined previously. There is a promising
new approach for treatment that relies on individual genomic differences termed
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personalized medicine. The idea is that each person’s disease has a unique susceptibility
based on their “genomic blueprint” (“Personalized Medicine,”). It is essential that
research continues into the mechanisms regulating tumorigenesis and specifically, it is
important to gain a better understanding of gene families such as the TNFAIP8 gene
family because they provide greater insight into the mechanisms that govern
tumorigenesis. Other priorities include increasing political commitment to cancer
prevention, monitoring cases and costs, as well as developing standard tools and
treatment methods (World Health Organization, 2018).
Lung Cancer
Cancers that form in tissues of one or both lungs, usually in the cells that line
airways, are referred to as lung cancer. Lung cancer begins when cells of the lung(s)
begin to grow and divide abnormally, allowing them to form tumors and spread to other
areas of the body (American Cancer Society, 2018a, 2018b). There are two major forms
of lung cancer, non-small cell lung cancer and small cell lung cancer. Non-small cell lung
cancer makes up 80-85% of all lung cancers, with the other 10-15% being small cell lung
cancers. Lung cancers are the second most common cancer in men and women, excluding
skin cancer, (American Cancer Society, 2018b) and are the leading cause of cancer
deaths in males and females in the United States (Figure 2).
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Figure 2. Top ten cancer types in males and females in 2017 in the United
States. Top shows estimated new cases and bottom shows estimated
deaths. Lung cancer is leading in cancer deaths among both sexes.
(Siegel et al., 2017). Copyright © 2017, John Wiley and Sons.
Reprinted by permission from John Wiley and Sons (4339050472934).
Cancer Journal for Clinicians. Siegel, R. L., Miller, K. D., & Jemal, A.
(2017). Cancer statistics, 2017. CA: A Cancer Journal for Clinicians,
67(1), 7–30. https://doi.org/10.3322/caac.21387
Smoking cigarettes is the number one risk factor for developing lung cancer and
is linked to 80-90% of all lung cancers. Smoking increases the risk of developing lung
cancer by 15 to 30 times. Second-hand smoke is also linked to an increased risk of
development of lung cancer, especially when children are between the ages of 3-11 years
old (Center for Disease Control and Prevention, 2017). While the survival rates for most
cancer diagnoses have increased, lung cancer mortality rates remain high. The 5-year
survival rate for lung cancer is 18%, which is partially attributable to the fact that most
8

cases are caught in late stages. Over 50% of cases are diagnosed at a stage where
treatment is rarely effective. Of lung cancer cases diagnosed in late stages, only 4% of
patients live for more than 5 years (Siegel, Miller, & Jemal, 2017). This demonstrates the
need for new and more effective prevention, detection, and treatment protocols.
Mammalian Cell Culture and NCI-H1299 Cells as Model
The NCI-H1299 (H1299) cell line is derived from the lymph node metastasis of a
non-small cell lung carcinoma in a 43-year-old Caucasian male. The cells do not express
p53 protein, a known tumor suppressor, due to a homozygous partial deletion. They do
have the ability to produce neuromedin B, but not gastrin releasing peptide. Both
neuromedin B and gastrin releasing peptides are the mammalian homologs of bombesin,
which is a protein used as a tumor marker in small cell lung cancer and stomach cancer
among others (American Type Culture Collection, 2016; Wang, Knezetic, Schally, Pour,
& Adrian, 1996). H1299 cells are adherent epithelial cells that can be used as a
mammalian cell culture model and are suitable for transfections (American Type Culture
Collection, 2016).
Cell culture can be used as an in vitro or in vivo model, but is generally used in
two-dimensional (2D) cell culture as an in vitro model. To be used as an in vivo model,
H1299 cells are typically transplanted into recipient animal models such as mice. These
xenotransplantation models are often used as an initial step in research to understand how
cancer cells of various types behave in a live organism (Giovanella, Yim, Stehlin, &
Williams, 1972). A possible bridge between 2D in vitro studies and in vivo studies are
those of three-dimensional (3D) cell culture. In typical 2D cell culture, cells are cultured
on flat plastic flasks, or dishes in medium suited for the particular cells to grow in. The
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cells are then grown in a monolayer and passaged, until used for further experimentation.
This method has benefits of being fast, easy, and cost-effective; however, it also has its
drawbacks. Cells grown in 2D culture exist in a monolayer composed of growing and
dividing cells, where all dead cells have detached from the culture vessel. The dead cells
are then removed with each passaging. Also, cells grown in 2D models are more
stretched out and flat than they normally grow leading to an abnormal cell morphology.
This abnormal morphology could have influences over processes of interest such as cell
proliferation, gene expression, and protein expression. Overall, these cells may not
behave as they would in vivo (Edmondson, Broglie, Adcock, & Yang, 2014). On the
other hand, 3D cell culture is becoming more popular as it has all the benefits of 2D cell
culture and being an in vitro model, however it better mimics the microenvironments of
in vivo studies. The cells are cultured using hydrogel or an agar layer to allow cells to
grow in all directions. This model allows cells to interact with each other in a way more
accurate to in a live model. It is important to note that the 3D system also has drawbacks
in the ways that you have cells growing together, but they do not possess vascular
systems so the passage of waste, nutrients, and oxygen are only carried out by diffusion.
This limits the size of spheroids that can be grown and what types of cells can be used
(Edmondson et al., 2014).
Overall, cell culture allows the cells removed from various animal or plant tissues
to be grown in artificial media. After cells are isolated and grown up on artificial media
to a point where they must be passaged, they become cell lines. Cell lines are
immortalized through acquisition of genetic mutations that allow them to grow and these
cell lines can then be continually passaged and used in research. The culture conditions
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for each cell type vary, but they all require essential nutrients such as amino acids,
carbohydrates, and gas exchange. Cell culture is one of the most important tools available
to study biochemical processes and allows for results to consistent and reproduced (Cell
Culture Basics Handbook, 2016). It also provides the advantage of being relatively easy,
and cost effective.
In this study, the H1299 cell line was used as a 2D model, where a monolayer of
cells is grown in a tissue culture flask or dish and then passaged for continuation of the
cell line.
TNFAIP8 Gene Family
The tumor necrosis factor-alpha-induced protein 8 (TNFAIP8) gene family is a
recently discovered family that has been found to be involved in regulation of
tumorigenesis, inflammation, and immunity (Lou & Liu, 2011). The four members
TNFAIP8, TNFAIP8L1, TNFAIP8L2 , and TNFAIP8L3 all encode for proteins with a
unique structure that includes seven alpha helices surrounding a central hydrophobic
cavity (Sullivan et al., 2017). The gene family members TNFAIP8 and TNFAIP8L2 are
activated by TNF-α in times of environmental stress. Since discovery of this gene family,
there have been many studies to elucidate structure and function of the members,
however TNFAIP8L1 still remains uncharacterized. TNFAIP8 functions as a tumor
promoter or tumor suppressor, depending on the splicing variant (Lowe et al., 2017) and
has been associated with lung, blood and bone cancers among others. TNFAIP8L1
functions as a tumor suppressor and has been linked to liver and lung cancer, but the
mechanism by which it exerts this function has yet to be elucidated. TNFAIP8L2 is also
classified as a tumor suppressor and has also been linked to liver and lung cancer. The
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last member, TNFAIP8L3, has been shown to function as a tumor promoter and is
associated with lung, cervix, and colon cancers (Table 1).
TNFAIP8
TNFAIP8, also known as SSC-S2, GG2-1,
and MDC-3.13, is an oncogenic protein and
apoptotic regulator (X. Zhang et al., 2009). It was
the first gene family member described and is one
of the most well characterized genes in the family
along with TNFAIP8L2. It has been shown to act as
either a tumor promotor or tumor suppressor
Figure 3. Proposed mechanism by
which TNFAIP8 splice variant 2
performs its function as a tumor
promotor.

depending on the splice variant and cell type
affected (Kumar et al., 2004; Lowe et al., 2017).

One study showed that variant 2 is overexpressed in many human cancers including lung
adenocarcinoma, lung squamous cell carcinoma, and hepatocellular carcinoma, where
variant 1 of TNFAIP8 is downregulated and variants 3,4,5 and 6 are expressed at very
low levels (Lowe et al., 2017). The proposed mechanism by which variant 2 promotes
cancer is through p53 repression, in effect cancelling out its ability to induce apoptosis
and inhibit tumorigenesis. TNFAIP8 has also been hypothesized to protect cells against
apoptosis through inhibiting Rac1 (Figure 3). The TNF-a cytokine activates the tumor
necrosis factor receptor (TNFR), which activates Rac1 and NF-kB. Rac1 is responsible
for promoting cell death through the ultimate promotion of reactive oxygen species
(ROS), but the TNFR also activates NF-kB which increases TNFAIP8 expression
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allowing it to inhibit Rac1 and therefore stopping the production of ROS and cell death
(Porturas et al., 2015).
TNFAIP8L1
TNFAIP8L1 is expressed in many tissues, and a study in mice revealed that
TNFAIP8L1 was found in tissues ranging from neurons in the brain, muscle tissue, and
hepatocytes, as well as many cells of epithelial origin. This is important because
epithelial tissues play a role in many processes such as absorption, secretion, and
immunity (Cui et al., 2011). TNFAIP8L1was shown to induce apoptosis in hepatocellular
carcinoma cells (HCC) by negatively regulating Rac1 and altering down-stream pathway
activations (Z. Zhang et al., 2015). This is comparable to the proposed mechanism by
which TNFAIP8 carries out its functions. TNFAIP8L1 has also been shown to inhibit the
growth of lung cancer, with low levels expressed in tumor tissue (Wu et al., 2017).
Decreased levels of TNFAIP8L1 have been correlated with poor patient survival and have
led to the hypothesis that it can be used as a negative prognostic indicator for lung cancer
patients (Wu et al., 2017). To fully understand the function of TNFAIP8L1, we must
understand the structure. It is hypothesized that the structure of TNFAIP8L1 is very
similar to TNFAIP8L2, which is composed of 7 anti-parallel alpha helices. There is also a
central hydrophobic cavity which is a potential site for co-factor binding and may play a
role in immune homeostasis (X. Zhang et al., 2009). Based on this known structure of
TNFAIP8L2 and the comparison of each amino acid residue among the gene family
members (Figure 4,5)(Sullivan et al., 2017), it is suggested that TNFAIP8L1 has a
similar structure as described for TNFAIP8L2.
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Comparison of amino acid sequences encoded for by each member
of the TNFAIP8 gene family using Clustal Omega analysis. (B) Quantification
of sequence identity between gene family members reported as percentage of
shared amino acid sequence. Figure reprinted under the terms of the Creative
Commons Attribution License. PLOS ONE. © 2017 Sullivan et al.
Figure 4. (A)

TNFAIP8L2
TNFAIP8L2 along with TNFAIP8 is the most well characterized of the gene family
members. A study in 2009 revealed a previously uncharacterized fold that differed from
the prior hypothesis that TNFAIP8L2 had a death effector domain (DED) important to
the execution of its function as a tumor suppressor. This fold was discovered following
the elucidation of a high-resolution crystal structure of TNFAIP8L2. It also revealed a
large, central hydrophobic cavity that is most likely the site for co-factor binding and
14

phosphoinositide second messenger
binding (Figure 5) (Fayngerts et al.,
2014b; X. Zhang et al., 2009).
TNFAIP8L2 plays an important role
in immune homeostasis and has also
been shown to inhibit human
hepatocellular carcinoma metastasis
in HCC-derived cells lines. A study

Figure 5. (a)The overall structure of TNFAIP8L2
showing all six alpha helices. (b) TNFAIP8L2
topology is different than that of the DED domain
(X. Zhang et al., 2009). Reprinted by permission
from Springer Nature: Zhang, X., Wang, J., Fan, C.,
Li, H., Sun, H., Gong, S., … Shi, Y. (2009). Crystal
structure of TIPE2 provides insights into immune
homeostasis. Nature Structural and Molecular
Biology, 16(1), 89–90.
https://doi.org/10.1038/nsmb.1522

of 112 patients showed that loss
or reduction of TNFAIP8L2 in
primary HCC tissues led to
greater metastasis. It was
discovered that the cause is that

TNFAIP8L2 inhibits the migration and invasion of cancer cells through inhibition of
Rac1(Cao et al., 2013). This targeting of Rac1 is consistent with studies performed using
TNFAIP8 and TNFAIPL1 and shows a similarity in execution of tumor suppression.

TNFAIP8L3
TNFAIP8L3 is a cytoplasmic protein that is expressed in various mouse and
human tissues, but generally restricted to cell types of epithelial origin. High levels have
been detected in the digestive tract, the islets of the pancreas, and breast duct epithelial
cells (Cui et al., 2015). The protein expression similarities between human and mice may
15

be due to the homologous sequences they share and this trend of tissue specific
expression has been shown in studies of other gene family members (Chen et al., 2016;
Cui et al., 2011, 2015). TNFAIP8L3 has been shown to function as the transfer protein of
phosphoinositide second messengers that promote cancer. Similar to the structure of
TNFAIPL2, it has a large hydrophobic cavity that can bind lipid second messengers
(Fayngerts et al., 2014b). In human cancers associated with TNFAIP8L3 upregulation
subsequent knockout of TNFAIP8L3 results in decreased tumorigenesis. Conversely in
cell culture, when TNFAIP8L3 expression is forced, tumorigenic effects are increased
(Fayngerts et al., 2014b).
Interactomics
Interactomics is the study of protein-protein interactions and their implications
using scientific experimentation and bioinformatics for analysis. The study of protein
interactions is necessary for understanding cellular function and more complex pathways
where proteins are interacting (Dammeyer & Schobert, 2010). There are many different
techniques for studying and/or validating these interactions including coimmunoprecipitation coupled with mass spectrometry, yeast two-hybrid assays,
mammalian two-hybrid assays, proximity ligation assays, and bimolecular fluorescence
complementation (Table 2).
Utilizing mass spectrometry based proteomics allows the protein itself to be used
to isolate its binding partners. In the past, yeast two hybrids were used, but the
advantages of co-immunoprecipitation with mass spectrometry analysis include that
multi-component complexes can be isolated with only one step, and that it utilizes the
protein of interest in its processed form (Free, Hazelwood, & Sibley, 2009). Data indicate
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that mass spectrometry coupled with co-immunoprecipitation is a quick, safe, and
efficient way of identifying protein-protein interactions. It is one of the best tools
available for elucidating previously unknown protein partners due to the volume of data
and interactors that can be processed (Moresco, Carvalho, & Yates, 2010).

Interactomics Technique
Co-immunoprecipitation
and Mass Spectrometry

Mammalian Two-Hybrid
Assay
Yeast Two-Hybrid Assay

Proximity Ligation Assay
Bimolecular Fluorescence
Complementation

Advantages
Isolation of protein
complexes, protein of
interest is in processed
form, large scale, time
effective

Disadvantages
Not all interactors are true
interactors, not able to
resolve interactors in
complexes, does not
validate specific
interactions
Fast, inexpensive, flexibility Direct interactors only,
of interactors
some proteins can be toxic
to host cells
Eukaryotic form, can be
Direct interactors only,
scaled up easily
interacting proteins must
move to the nucleus,
proteins not in natural
environment, issues with
post translational
modifications occurring
properly
Easy, sensitive, can closely
mimic natural environment
for the protein
Allows for tracking of
interactions over time and
changing conditions,
sensitive, can detect direct
and indirect interactors

Direct interactors only,
increased cost, increased
time for result output
Requires expensive
equipment, not best choice
for direct interactions

Table 2. Summary of the advantages and disadvantages of the major interactomics techniques used for
studying and validating protein-protein interactions.

Mass Spectrometry
Mass Spectrometry is an analytical technique that separates ions based on their
mass-to-charge ratio. Two particles with the same mass-to-charge ratio will separate in
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the same way. The first step is ionization of the sample, where electrons are removed to
give the sample a positive charge. Post ionization, the ions are accelerated to a uniform
kinetic energy and subjected to a magnetic field. Deflection of the ions as they pass
through the magnetic field will vary based on their size and charge, giving a mass-tocharge ratio. Smaller ions and ions with the greatest charge are deflected at a higher rate.
The beam of ions passes through a detector that allows a spectral fingerprint to be
recorded (Breci, 2017). The spectral data are reported as relative abundance versus massto-charge ratio. These are then entered into a spectral database for analysis and
determination of protein identity (Cottrell, 2011).
Instrument

Advantages

Disadvantages

Quadrupole Mass
Analyzer

Relatively cheap and
fast, reproducible results

Lower resolving power,

Time of Flight Mass
Analyzer

Fast, sensitive, increased
molecular weight rangeuseful for biological
samples

Limited dynamic range

Quadrupole Ion Trap
Mass Analyzers

Qualitative work (i.e
protein identification),
sensitive, high resolution

Quantitative work, not
optimal for work with
masses below 100 Da,
Low scan rate

Table 3. Advantages and disadvantages of widely used mass analyzers.
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MATERIALS AND METHODS

Cell Culture
NCI-H1299 Cell Line was grown in Roswell Park Memorial Institute (RPMI1640) Medium (Corning®, Corning, New York), supplemented with 10% Fetal Select
serum (Atlas Biologicals, Fort Collins, Colorado). The cells were grown in T-25 tissue
culture flasks and incubated at 37°C, 5% CO2. Cells were passaged every 2-3 days at 8090% confluency.
Creation of a Stable Gene Overexpression
Antibiotic Sensitivity Curve
An antibiotic sensitivity curve assay was performed using the NCI-H1299 Cell
Line to determine an optimal selection concentration of Geneticin™ selective antibiotic
(G418 Sulfate – Gibco County Dublin, Ireland) to be used for selection of successful
transformants. Cells were plated at 50,000 cells/well in a 12 well plate and grown
overnight in RPMI-1640 medium (Corning®). Twenty-four hours post-plating; varying
Geneticin™ selective antibiotic (G418 Sulfate – Gibco) concentrations were added to the
wells. Concentrations ranged from 0.0 mg/mL (Control) to 1.2 mg/mL. RPMI-1640
medium was replaced every 48 hrs with cell cytopathic effects and cell death observed
every 24 hrs for 14 days for the lowest concentration that killed 100% of cells.
Stable Line Generation - Transfections
One day prior to transfection, cells were plated at 50,000 cells per well in a 24
well plate in RPMI-1640 (Corning®) medium and 10% Fetal Select serum (Atlas
Biologicals). The next day, NCI-H1299 cells were transfected with 0.5 ug pcDNA3.1+/c-
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(k)-DYK empty vector (GenScript, Piscataway, New Jersey), pcDNA3.1+/c-(k)-HPRTDYK (GenScript) or pcDNA3.1+/c-(k)-TNFAIP8L1-DYK (GenScript) using DNA-In®
transfection reagent (Molecular Transfer Inc., Gaithersburg, Maryland) according to
manufacturer’s instructions. The transfection process forced the cells to express
TNFAIP8L1 or HPRT1 respectively, while the empty vector transfection was used as a
control to verify that the plasmid itself or the transfection method was not cytotoxic to
our cells. In the pcDNA3.1+/c-(k)-DYK plasmid, the DYK portion encodes for a FLAG
tag which can be used to isolate the protein and protein interests of complexes through
utilization of anti-FLAG antibodies. In the twenty-four hours-post-transfection, medium
replaced with fresh RPMI-1640 (Corning®) medium and 10% Fetal Select serum (Atlas
Biologicals). Forty-eight hours-post-transfection, cells were trypsinized with 0.25%
trypsin EDTA (1x) (Gibco) and transferred to T-25 flasks. Seventy-two hours-posttransfection, RPMI-1640 medium containing 10% Fetal Select serum (Atlas Biologicals)
and 0.75 mg/mL Geneticin™ selective antibiotic (G418 Sulfate-Gibco) was added to
cells to select for successful transformants. Future passages of transfected cells used
RPMI-1640 medium with 10% Fetal Select serum (Atlas Biologicals) and 0.75 mg/mL
Geneticin™(Gibco) in order to continue selection of successful transformants.
Transient Gene Overexpression
NCI-H1299 Cells were used at 90% confluence in T-25 flasks containing RPMI1640 (Corning®) medium and 10% Fetal Select serum (Atlas Biologicals). NCI-H1299
cells were transfected with 5.0 ug pcDNA3.1+/c-(k)-DYK empty vector (GenScript),
pcDNA3.1+/c-(k)-HPRT-DYK (GenScript) or pcDNA3.1+/c-(k)-TNFAIP8L1-DYK
(Genscript) using DNA-In® transfection reagent (Molecular Transfer Inc.) according to
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manufacturer’s instructions. All flasks were co-transfected with 1.0 ug
pAdVAntage™(Promega, Madison, Wisconsin), to increase protein expression of interest
by increasing initiation of translation. Twenty-four hours-post-transfection, medium was
replaced with new RPMI-1640(Corning®) medium and 10% Fetal Select (Atlas
Biologicals). Forty-eight hours-post-transfection cells were lysed for coimmunoprecipitation.
Co-Immunoprecipitation
In order to determine putative protein interactors, TNFAIP8L1 and the interacting
proteins were isolated from the cell lysate by co-immunoprecipitation. H1299 cells stably
expressing TNFAIP8L1and HPRT1 were lysed in Pierce™ IP Lysis Buffer
(ThermoFisher Scientific, Waltham, Massachusetts) containing Halt™ protease and
phosphatase inhibitors (ThermoFisher Scientific) for thirty mins with constant agitation at
4°C on a rotator. Following thirty-minute lysis, lysate was microcentrifuged for twenty
mins at12,000 RPM at 4°C. Supernatant was added to Anti-FLAG® M2 Magnetic Beads
(Sigma-Aldrich, St. Louis, Missouri) and incubated overnight with constant agitation at
4°C on a rotator. Beads were washed with TBST (Tween-20 at 0.05%) and eluted in 2x
Laemmli sample buffer (Bio-Rad, Hercules, California) containing 5% 2mercaptoethanol (2-ME) and boiled at 100°C for three mins. Eluate was used for western
blot analysis and/or mass spectrometry analysis.
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Figure 6. Co-immunoprecipitation schematic beginning with lysis of cells through incubation with AntiFLAG© M2 Magnetic Beads (Sigma), wash steps and elution for western blot and mass spectrometry
analysis.

Western Blots
Western blots were performed to determine that TNFAIP8L1 and HPRT1 were
present in our transfected cells and therefore suitable for the next steps. Eluate in 2x
loading dye with 5% 2-ME was loaded on Mini-PROTEAN© TGX™ Pre-Cast gels (BioRad). The PAGE gel was run in 1x Tris/Glycine/SDS Buffer (Bio-Rad) at 150 volts for
30 to 50 mins. Chameleon Duo Pre-Stained Protein Ladder was used as a standard (LICOR Biosciences, Lincoln, Nebraska). Proteins were transferred to a nitrocellulose
membrane in 1x Turbo Transfer Buffer using a Trans-Blot® Turbo™ Transfer System
(Bio-Rad), according to the manufacturer’s protocol. REVERT™ Total Protein stain (LICOR) was used according to manufacturer’s protocols prior to blocking blots in nonfat
dried milk for visualization of potential protein interactors pulled out during coimmunoprecipitation. Blots were imaged on the Odyssey® CLx Infrared Imaging System
(LI-COR). Membrane was then blocked in 5% non-fat dried milk in TBST (0.1% Tween
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20) for 60-90 mins before incubation with rabbit DYKDDDDK tag polyclonal antibody
(2 ug/mL) (Invitrogen, Carlsbad, California) overnight at 4°C on a nutator (Fisher
Scientific, Hampton, New Hampshire). The nitrocellulose membrane was rinsed two
times with TBST and then washed three times with TBST for 5 mins each on a rocking
platform. Post washing, blot was incubated with IRDye®800CW Donkey anti-Rabbit
secondary antibody (70 ng/mL) (LI-COR) for 1 hr in the dark at room temperature on a
rocker. Blot was washed three times with TBST and two times with TBS before imaging
on the Odyssey® CLx Infrared Imaging System (LI-COR).
Mass Spectrometry
Protein identification was achieved through Ultra-performance liquid
chromatography-tandem mass spectrometry on the Q-Exactive HF-X quadrupoleOrbitrap mass spectrometer (ThermoFisher Scientific). Protein identification completed
using Comet and Tandem spectral libraries. Samples were processed by Dr. Brian
Balgley at Bioproximity (Chantilly, Virginia).
Sub-cloning
PCR amplifications of TNFAIP8L1, DVL3 and FBXW5 inserts were performed
in 50 uL reactions with (1x) Q5® reaction buffer (New England BioLabs, Ipswich,
Massachusetts), 200 nM dNTP mixture, 0.02 U/uL Q5® polymerase (New England
BioLabs), 1.0 ng of template and 0.5 uM of respective primers (Table 4). PCR
amplification of TNFAIP8L1, DVL3 and FBXW5 was run at a reaction protocol of
incubation at 98°C for 30 seconds, followed by 20 cycles of 98°C for 10 seconds, 60°C
for 15 seconds, 72°C for 75 seconds, and then 72°C for 5 mins and held at 12°C.
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Insert
Forward Primer (BamHI)
TNFAIP8L1 ACGTAT GGATCCGT ATGG
ACACCTTCAG CACCAAG

Reverse Primer (NotI)
ACGTAT GCGGCCGC
TCAGAGGCTGCCCTCGTCCAG

FBXW5

ACGTAT GGATCCGT
ATGGACGAGGGCGGCACGCC

ACGTAT GCGGCCGC
TCAGCGCCTCTGGCTGGCAAG

DVL3

ACGTAT GGATCCGT
ATGGGCGAGACCAAGATCAT

ACGTAT GCGGCCGC
TCACATCACATCCACAAAGAA

Table 4. Forward and reverse primers used in PCR amplification of inserts TNFAIP8L1,
DVL3 and FBXW5.
Restriction digestion of PCR products was performed using BamHI and Not1 to
create compatible ends for ligations with pACT and pBIND vectors used in mammalian
two-hybrid assays. Similarly, pACT and pBIND were subjected with restriction
digestions with BamHI and NotI. Ligations were performed to generate fusion proteins
with all plasmids and inserts (Table 5) with 50 ng vector and a 1:3 vector to insert ratio.
Nuclease free water, 10x T4 ligase buffer (New England BioLabs), 50 ng vector, insert
and T4 DNA ligase (New England BioLabs) were combined and ligation was run at RT
for 1 hr. Ligations were then immediately used in transformations. One Shot™ Top10
competent Escherichia coli cells (ThermoFisher Scientific) were transformed and plated
on LB-AMP (100 ug/mL) plates for selection of successful transformants. Colonies were
picked and grown in LB-AMP liquid media (100ug/mL) overnight at 37°C with constant
shaking. Plasmid DNA was isolated after 16 hrs using QIAprep® Spin Miniprep Kit
(QIAGEN, Hilden, Germany). Glycerol stocks were made of all mini preps by adding 1
part of respective miniprep to 1 part 65% glycerol (0.1M MgSO4, 0.025 M Tris-HCl, pH
8.0) and mixing well, then placing in -80°C.
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The success of ligation was then determined for each individual transformant by
separating the restriction digestion on a 1.5% agarose gel to identify correct restriction
digestion pattern. The plasmids (Table 5) were then analyzed for correct, in-frame
sequence by DNA sequencing (University of Maine Sequencing Facility) with T7 EEV
primer (Promega).
Plasmids
Positive Control: pACT-MyoD and
pBIND-ID
Negative Control: pBIND and pACT
pACT-TNFAIP8L1
pACT-DVL3
pACT-FBXW5
pBIND-TNFAIP8L1
pBIND-DVL3
pBIND-FBXW5

Fusion Proteins
Encodes for VP16-MyoD and GAL4-Id
fusion proteins, respectively.
Encode for no fusion proteins
Encodes for VP16-TNFAIP8L1
Encodes for VP16-DVL3
Encodes for VP16-FBXW5
Encodes for GAL4-TNFAIP8L1
Encodes for GAL4-DVL3
Encodes for GAL4-FBXW5

Table 5. Summary of plasmids and fusion constructs used in mammalian two-hybrid
assay.
Subcloning of Mammalian-Two Hybrid Assay Plasmids
One Shot™ Top10 competent Escherichia coli cells (ThermoFisher Scientific)
were transformed using the pACT, pBIND and pG5luc vectors from the CheckMate™
Mammalian Two-Hybrid System (Promega) and plated out onto LB-AMP (100 ug/mL)
plates for selection of successful transformants. Colonies were picked of successful
transformants and grown in LB-AMP liquid medium (100 ug/mL) overnight at 37°C with
constant shaking. Plasmid DNA was isolated after 16 hrs using QIAprep® Spin Miniprep
Kit (QIAGEN, Hilden, Germany). Glycerol stocks were made of all minipreps by adding
one part of respective miniprep to one part 65% glycerol (0.1M MgSO4, 0.025 M TrisHCl, pH 8.0) and mixing well, then placing stocks in -80°C.
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Plasmids pcDNA3-myc3-FBXW5 (Addgene, Cambridge, Massachussets),
pDONR223-DVL3-WT (Addgene) and pcDNA3.1+/c-(k)-TNFAIP8L1-DYK
(GenScript) were quadrant streaked onto LB AMP plates (100 ug/mL). Colonies were
picked and grown up in LB AMP liquid medium (100 ug/mL) overnight at 37°C with
constant shaking. Plasmid DNA was isolated after 16 hrs using QIAprep® Spin Miniprep
Kit (QIAGEN). Glycerol stocks were made of all minipreps by adding one part of
respective miniprep to one part 65% glycerol (0.1M MgSO4, 0.025 M Tris-HCl, pH 8.0)
and mixing well, then placing stocks in -80°C.
Mammalian Two-Hybrid Transfections
H1299 Cells were plated at 5,000 cells/well in a white 96 well plate and grown
overnight in RPMI-1640 with 10% Fetal Select serum (Atlas Biologicals). The next day,
cells were transfected using DNA-In™ (Molecular Transfer Inc.) and respective pACT
and pBIND experimental plasmids (75 ng) and pG5luc (50ng) according to
manufacturer’s protocols (Promega) (Table 5). Transfected cells were placed in
incubator at 37°C, 5% CO2. Twenty-four hours later medium was replaced with fresh
RPMI-1640 medium (Corning®). Forty-eight hours-post-transfection; cells were used for
Dual-Luciferase® Reporter Assay (Promega).
Dual Luciferase Assay
Dual-Luciferase® Reporter Assay (Promega) Reagents were prepared according
to the manufacturer’s recommendations. Passive lysis buffer (PLB) was diluted to (1x) by
mixing 1 volume (5x) PLB and 4 volumes distilled water. Luciferase assay reagent II
(LARII) was prepared by re-suspending lyophilized luciferase assay substrate in
luciferase assay buffer II. Stop & Glo reagent was prepared by adding 200 uL of (50x)
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Stop & Glo Substrate to 10 mL of Stop & Glo Buffer in a glass vial. These volumes were
adequate for 100 assays.
Forty-eight hours-post-transfection, RPMI-1640 medium (Corning®) with 10%
Fetal Select serum (Atlas Biologicals) was removed from the H1299 cells and cells were
washed with (1x) Phosphate Buffered Saline (PBS). H1299 cells were lysed with (1x)
PLB for 15 mins at room temperature, on a rocker. Following lysis, cells were stored at 20°C. Forty-eight hrs later, cells were plated into a white 96 well plate for completion of
the protocol. The standard Dual-Luciferase® Reporter Assay (Promega) protocol was
performed according to manufacturer’s protocol using a GloMax® 96 Microplate Dual
Injector Luminometer (Promega). Relative interaction values reported are ratios of firefly
luciferase to Renilla luciferase.

Figure 7. Schematic diagram of mammalian two-hybrid assay. Two genes of interest were
cloned into the pACT and pBIND vectors to express proteins that have potential for
interaction. Fusion proteins were created expressing VP16-TNFAIP8L1, GAL4-DVL3,
GAL4-FBXW5 and VP16-DVL3, VP16-FBXW5, GAL4-TNFAIP8L1. The pG5luc Vector
contains GAL4 binding upstream of the firefly luciferase gene. The GAL4 and VP16 fusion
proteins were transfected along with the pG5luc Vector into H1299 cells. Two days post
transfection; the cells were lysed and analyzed using the Dual-Luciferase® Reporter Assay
System. The firefly luciferase production is relative to the protein-protein interaction
occurring, however there is also Renilla luciferase production encoded for by the pBIND
vector. This production allows for normalization of results to account for number of cells,
transfection efficiency and comparison across all constructs.
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RESULTS

Optimal selection concentration of Geneticin™ is 0.75 mg/mL in H1299 cells.
An antibiotic sensitivity assay was performed using the NCI-H1299 Cell Line to
determine an optimal selection concentration of Geneticin™ selective antibiotic (Gibco).
Cells were plated at 50,000 cells/well in a 12 well plate and grown overnight in RPMI1640 medium (Corning®). Twenty-four hours post-plating; varying Geneticin™ selective
antibiotic (G418 Sulfate – Gibco) concentrations were added to the wells. Concentrations
ranged from 0.0 mg/mL (Control) to 1.2 mg/mL. RPMI-1640 (Corning®) medium was
replaced every 48 hrs with cell cytopathic effects and cell death observed every 24 hrs for
14 days for the lowest concentration that killed 100% of cells. The concentration was
determined to be 0.75 mg/mL.
TNFAIP8L1-FLAG Overexpressed in H1299 cells.
An antibiotic sensitivity assay was performed using the NCI-H1299 Cell Line to
determine an optimal selection concentration of Geneticin™ selective antibiotic to be
0.75 mg/mL. H1299 cells were transfected with pcDNA3.1+/c-(k)-DYK empty vector
(GenScript), pcDNA3.1+/c-(k)-HPRT-DYK (GenScript) or pcDNA3.1+/c-(k)TNFAIP8L1-DYK. Verification of successful stable TNFAIP8L1 overexpression in
H1299 lung cancer cell line was completed through western blot analysis. Results
indicate that the TNFAIP8L1 transfection was successful with the presence of a band
around 18 kDa. The empty-FLAG negative control showed a band that was unexpected,
around 12.5 kDa. The HPRT1-FLAG positive control for non-specific binding was
visualized as a band around 19 kDa (Figure 8). The bands were seen at lower molecular

28

weights than we predicted based on the sizes of the proteins. TNFAIP8L1 was expected
to be seen around 20.8 kDa and HPRT1 around 25 kDa.
Figure 8. Lane 1 (left) showing immunoprecipitation
of a non-specific protein in control cells. Lane 2
(middle) shows presence of TNFAIP8L1 in H1299
Transfected cells. Lane 3 (right) shows successful
transfection of HPRT1 into H1299 Cell Line.
Chameleon Duo Pre-stained Protein Ladder was used
as a standard. H1299 cells stably expressing
TNFAIP8L1-FLAG and HPRT1-FLAG were lysed
and incubated with Anti-FLAG© M2 Magnetic Beads
overnight at 4°C. Beads were washed three times with
TBST (Tween-20 to 0.05%) before elution in 2x
Laemmli sample buffer containing 5% 2mercaptoethanol. Eluate in 2x loading dye with 5% 2ME was loaded on Mini-PROTEAN© TGX™ PreCast gel. Gel was run in 1x Tris/Glycine/SDS Buffer
(Bio-Rad) at 150 volts for thirty mins. Membrane
blocked in 5% non-fat dried milk in TBST (0.1%
Tween 20) for 60-90 mins before incubation with antiFLAG antibody (1:500) overnight at 4°C. Membrane
was washed three times with TBST for 5 mins each
before incubation with anti-rabbit secondary antibody
(1:15,000) for 1 hr. Blot imaged on the Odyssey® CLx
Infrared Imaging System (LI-COR).

Protein Interactions occurring with TNFAIP8L1.
To visualize all proteins bound to the nitrocellulose membrane and consequently
interactors pulled out during co-immunoprecipitation with TNFAIP8L1,
REVERT™ Total Protein Stain was used prior to blocking blot in non-fat dried milk. This
was used as an indicator that there was enough protein for detection by mass
spectrometry. Coomassie Blue staining of SDS-PAGE gel, or fluorescent staining and
visualization could have also been performed to visualize total proteins. Imaging at 700
nm showed interactors were present with both controls (empty vector and HPRT1), as
well as TNFAIP8L1-FLAG (Figure 9). The size of putative interactors has a range from
approximately 15-125 kDa. The heavy and light chains of the anti-FLAG M2 antibody
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are seen separately due to the presence of 2-mercaptoethanol breaking the antibody
chains apart.

Figure 9. REVERT™ Total Protein Stain was used prior to blocking blots in
non-fat dried milk for visualization of protein interactors pulled out during coimmunoprecipitation. Blot imaged on Odyssey® CLx Infrared Imaging
System (LI-COR). Bands indicate total protein. TNFAIP8L1-FLAG in lane 3
shows proteins pulled out with TNFAIP8L1 during co-immunoprecipitation.

TNFAIP8L1 has 138 putative protein interactors in H1299 lung cancer cell line model.
Identification of putative protein interactors with TNFAIP8L1 was performed
utilizing co-immunoprecipitation and mass spectrometry. Co-immunoprecipitation was
performed using Anti-FLAG© M2 Magnetic Beads. Beads were frozen and subsequently
eluted with FLAG peptide. Eluate was analyzed using Ultra-performance liquid
chromatography-tandem mass spectrometry on the Q-Exactive HF-X quadrupoleOrbitrap mass spectrometer (ThermoFisher) by Bioproximity. Protein identification was
completed using Comet and Tandem spectral libraries. There were 561 unique genes
encoding proteins that were interacting with our negative control (empty) and 181 unique
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genes encoding proteins that were interacting with our HPRT1 control for non-specific
binding. There were 31 genes encoding proteins that were interacting with both
TNFAIP8L1 and HPRT1, and 92 genes encoding proteins that were interacting with all
three. There were 138 unique genes identified that encode for proteins interacting solely
with TNFAIP8L1 (Figure 10, Table 6, Supplementary Table 1). The genes play
various roles in biological processes according to gene ontology analysis with the
PANTHER classification system. Of the 138 genes, 27% encode proteins involved in
cellular processes including cell recognition and cell cycle regulation (Figure 11). A web
of genes was analyzed to show protein interactions using NetworkAnalyst to visualize
interactors as they relate to specific processes and each other (Figure 12a). Interactors
involved in cell cycle regulation are shown in blue (Figure 12a) and pulled out for better
visualization (Figure 12b). The genes are shown in their biological networks to narrow in
on their relationships and commonalities in functions.
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Oliveros, J.C. (2007-2015)
Venny. An interactive tool for
comparing lists with Venn's
diagrams.
http://bioinfogp.cnb.csic.es/to
ols/venny/index.html

Figure 10. Venn diagram representing number of genes that encode for proteins interacting with
the proteins of interest. Green represents the empty-FLAG H1299 cells, yellow represent HPRT1FLAG and purple represents the TNFAIP8L1. There are 561,181 and 138 unique genes
respectively.
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Unique Interactors with TNFAIP8L1
ENSG0000000
7174
ENSG0000000
7933
ENSG0000005
3371
ENSG0000005
5044
ENSG0000005
5609
ENSG0000006
4787
ENSG0000006
6248
ENSG0000007
0367
ENSG0000007
3734
ENSG0000007
4071
ENSG0000008
0345
ENSG0000008
8387
ENSG0000010
0014
ENSG0000010
0804
ENSG0000010
5968
ENSG0000010
7863
ENSG0000010
8469
ENSG0000010
9189
ENSG0000011
0811
ENSG0000011
3327
ENSG0000011
3719
ENSG0000011
5705
ENSG0000011
6120

ENSG0000011
6544
ENSG0000012
0051
ENSG0000012
0251
ENSG0000012
2126
ENSG0000012
3219
ENSG0000012
5675
ENSG0000012
6001
ENSG0000012
6016
ENSG0000012
7507
ENSG0000012
8512
ENSG0000012
8881
ENSG0000013
0177
ENSG0000013
2746
ENSG0000013
3067
ENSG0000013
5406
ENSG0000013
5480
ENSG0000013
5517
ENSG0000013
6250
ENSG0000013
7522
ENSG0000013
7872
ENSG0000013
8600
ENSG0000013
8767
ENSG0000013
9990

ENSG0000014
0264
ENSG0000014
0326
ENSG0000014
0836
ENSG0000014
1068
ENSG0000014
2544
ENSG0000014
2784
ENSG0000014
3344
ENSG0000014
3952
ENSG0000014
4455
ENSG0000014
7381
ENSG0000014
8200
ENSG0000014
9503
ENSG0000015
2578
ENSG0000015
4252
ENSG0000015
5511
ENSG0000015
6136
ENSG0000015
6787
ENSG0000015
9433
ENSG0000016
0094
ENSG0000016
3110
ENSG0000016
3214
ENSG0000016
3904
ENSG0000016
3913

ENSG0000016
4032
ENSG0000016
4309
ENSG0000016
4506
ENSG0000016
4508
ENSG0000016
5078
ENSG0000016
7210
ENSG0000016
7332
ENSG0000016
7716
ENSG0000016
8264
ENSG0000016
8906
ENSG0000016
9594
ENSG0000017
0364
ENSG0000017
0485
ENSG0000017
1843
ENSG0000017
2464
ENSG0000017
4137
ENSG0000017
5221
ENSG0000017
5573
ENSG0000017
6624
ENSG0000017
6946
ENSG0000017
7030
ENSG0000017
7398
ENSG0000017
9869

ENSG0000018
0573
ENSG0000018
0938
ENSG0000018
1218
ENSG0000018
1752
ENSG0000018
3019
ENSG0000018
4260
ENSG0000018
5238
ENSG0000018
7166
ENSG0000018
7950
ENSG0000018
8171
ENSG0000018
8486
ENSG0000018
8487
ENSG0000019
6159
ENSG0000019
6218
ENSG0000019
6547
ENSG0000019
6646
ENSG0000019
6747
ENSG0000019
6787
ENSG0000019
6866
ENSG0000019
7535
ENSG0000019
7705
ENSG0000019
8863
ENSG0000020
3710

ENSG0000020
3812
ENSG0000020
5336
ENSG0000024
1127
ENSG0000024
6705
ENSG0000025
8839
ENSG0000026
0220
ENSG0000026
7680
ENSG0000027
0467
ENSG0000027
0505
ENSG0000027
2196
ENSG0000027
4997
ENSG0000027
5221
ENSG0000027
6021
ENSG0000027
6126
ENSG0000027
6289
ENSG0000027
6368
ENSG0000027
6903
ENSG0000027
7075
ENSG0000027
7603
ENSG0000027
8463
ENSG0000027
8677
ENSG0000028
1179
ENSG0000028
2988

Table 6. A comprehensive list of all 138 genes that encode for protein interactors with TNFAIP8L1
arranged by their ENSEMBL nomenclature.
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Biological Processes
Multicellular Organismal
Process
7.7%

Reproduction
0.4%
Response to
Stimulus
6.9%

Biological Regulation
12.9%

Cellular Component
Organization
12.4%
Metabolic Process
18.9%
Cellular Process
27%

Locomotion
1.3%

Localization
7.7%

Immune System Process
0.9%
Developmental Process
3.9%

Figure 11. Summary of 138 genes for unique protein interactors with TNFAIP8L1 as they relate to
biological processes using the PANTHER classification system for analysis.
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Figure 12 (A) Network that relates genes and proteins with known TNFAIP8L1
interactions to putative protein interactions from mass spectrometry data using Ingenuity
Pathways software. Dotted lines represent indirect interactions and solid lines represent
direct interactions. White shapes are presumably primary interactors and grey shapes,
secondary interactors. Network Shapes defined in key to the right of the figure. (B) Cell
Cycle interactors singled out from other interactors (Xia 2015, 2018). (C) Circadian
rhythm interactors singled out from other interactors (Xia 2015, 2018).

TNFAIP8L1 does not interact directly with DVL3 or FBXW5.
Validation of expected protein-protein interactions with TNFAIP8L1 from
research previously published (Chatr-Aryamontri et al., 2017; Ha et al., 2014) was not
verified through mammalian two-hybrid assay. Relative interaction was calculated as a
ratio of firefly luciferase activity to Renilla luciferase activity and reported as individual
points representing replicates (Figure 13, Supplementary Figure 1). Renilla luciferase
activity is encoded for in the pBIND vector allowing stable activity of Renilla to be used
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as an internal control. This activity is independent of interactions and allows for
normalization between samples with different cell numbers and transfection efficiencies.
Controls were performed with 4 replicates each and experimental wells had 8 replicates
for each. TNFAIP8L1 was expected to interact with DVL3 and FBXW5, but our results
did not support evidence of an interaction. FBXW5 was validated as an interactor with
TNFAIP8L1 (Ha et al., 2014) and DVL3 was previously determined to be a potential
interactor, but not validated (Rual et al., 2005).
B a it + P r e y
VP16 + GAL4
V P 1 6 -M y o D + G A L 4 -Id
V P 1 6 -T N F A IP 8 L 1 + G A L 4
V P 1 6 -T N F A IP 8 L 1 + G A L 4 -T N F A IP 8 L 1
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Figure 13. Results of mammalian two-hybrid assay. The fusion construct VP16-MyoD +
GAL4-Id was used as a positive control. Relative interaction was calculated as a ratio of firefly
luciferase activity to Renilla luciferase activity. Individual points represent replicates. Controls
were performed with 4 replicates each and experimental wells had 8 replicates for each. No
significant interaction between experimental constructs was seen in either experiment.
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DISCUSSION

With cancer near the top of the most prevalent diseases list for diagnoses and fatalities
and poised to stay there, it is critical to understand the processes that govern it. An
expanded understanding of tumorigenesis pathways and proteins that act in these
pathways can guide us to new prevention tactics as well as to better aimed treatment
options, which are highly sought after today. Previous studies of TNFAIP8L1 since its
discovery in 2008 have left it relatively uncharacterized, and surrounded by many
questions about its role in tumorigenesis and immunity. The putative protein interactors
identified in this study provide a place to start when looking at its role and functions as a
tumor suppressor.
There were 138 putative protein interactors with TNFAIP8L1 identified in this
study (Table 6, Supplementary Table 1). A gene ontology study using the PANTHER
(Protein ANalysis THrough Evolutionary Relationships) classification system revealed
that there was a wide variety of biological processes implicated by interactors. The
majority encoded for proteins involved in cellular processes (27%), followed by
metabolic processes (18.9%), biological regulation (12.9%), cellular component
organization (12.4%), multicellular organismal processes (7.7%), localization (7.7%),
response to stimulus (6.9%), developmental processes (3.9%),locomotion (1.3%),
immune system processes (0.9%) and reproduction (0.4%) (Figure 11). The cellular
processes portion was further broken down into cell communication (54.3%), cellular
component movement (20%), cell cycle regulation (11.4%), cell growth (5.7%), cell
recognition (5.7%), and cytokinesis (2.9%). The data suggest the TNFAIP8L1 plays a
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role in many different biological processes and pathways particularly those involving
cellular processes such as cell communication and the cell cycle (Figure 12b). It is also
interesting to note that only 0.9% of genes encoding proteins that interacted with
TNFAIP8L1 control immune system processes, as it is believed that the TNFAIP8 gene
family plays a role in immunity.
There were several genes of interest that were pulled out including melanomaassociated antigen 4 (MAGEA4) and angiomotin (AMOT) (Figure 12a). MAGEA4
encodes for the following proteins C9JK50, C9JIR1, Q1RN33, C9JZJ5, P43358,
Q4V9T5, C9J9C2 pulled out in the mass spectrometry analysis of interactors. The
MAGE-A gene family is expressed in numerous solid tumors, but silent in normal tissues
except for male germline cells, which do not carry human leukocyte antigen (HLA)
molecules. The proteins encoded for by the MAGE-A family are recognized by cytotoxic
T-lymphocytes and allow for an immune response against tumor tissue (Hamosh, Scott,
Amberger, Valle, & McKusick, 2000). In a study from 2000, 28% of patients with
Hodgkin’s lymphoma expressed MAGEA4 indicating that MAGEA4 may be involved in
Hodgkin’s lymphoma and a target for immunotherapy (Chambost et al., 2000).
Angiomotin (AMOT) is believed to play a role in the formation of new blood
vessels, a process termed angiogenesis, and its regulation. Angiogenesis is necessary for
tumors to grow and is therefore a topic of interest in tumorigenesis studies. AMOT has
also been implicated in WNT signaling pathways, which is key for regulating
development and previously associated with cancer (Z. Li et al., 2012). The WNT
pathway is involved in signaling to the disheveled protein family, which includes DVL3.
This link between TNFAIP8L1, AMOT, the WNT pathway and DVL3 could be
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significant in understanding the underlying mechanisms of tumorigenesis and how
TNFAIP8L1 plays a role.
Another interactor of interest was Neuronal PAS Domain Protein 2 (NPAS2), as it
is associated circadian rhythm pathways (Figure 12c) and related genes (DeBruyne,
Weaver, & Reppert, 2007; Landgraf, Wang, Diemer, & Welsh, 2016). The circadian
clock is an internal time keeping system that regulates physiological processes and
ultimately rhythms in gene expression that alter metabolism and behavior. Circadian
rhythms regulate processes that alter physical, mental and behavioral changes. The
rhythms can be disrupted and disruptions are linked to an increased risk of cancer
development. In 2001, the Fred Hutchinson Cancer Research center showed nurses who
regularly work the night shift were more likely to be diagnosed with cancer (Engel, 2014)
and 10 years ago the International Agency for research on cancer classified night shift
work as carcinogenic. While there is link between circadian disruption and cancer, as
well as TNFAIP8L1 and circadian rhythm pathways, the mechanism of the links are
unknown. TNFAIP8L1 may be playing a role in this pathway and its regulation in
tumorigenesis.
These putative protein interactions, once validated, will lead to increased
understanding of protein interaction pathways regulating the mechanism of tumorigenesis
and ultimately the TNFAIP8L1 binding partners may serve as potential partners for
future drug therapy and cancer prevention/treatment options.
The mammalian two-hybrid validations in this experiment did not support our
hypothesis or previous data suggesting FBXW5 and DVL3 interact directly with
TNFAIP8L1. Issues validating interactors may be because they are not directly binding
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TNFAIP8L1, but are part of a larger complex of proteins, or it is also possible that our
system does not allow for post translational modifications to occur that are required for
binding. Conversely, there could be post translational modifications occurring that are not
true to biological function.
In the future validation of putative TNAIP8L1 protein interactors could be
performed using mammalian two-hybrid assays, but considerations of the systems
shortcomings should be considered. A proximity ligation assay or other means of
visualizing interactions such as bimolecular fluorescence complementation may be
necessary. Performing a similar protein interaction study with TNFAIP8, TNFAIP8L2,
and TNFAIP8L3 would be beneficial in increasing our understanding of the gene family,
but also elucidate possible pathways to study for the individual members. Validated
interactions should lead into mutagenesis studies to identify specific binding domains of
TNFAIP8L1 and its binding partner as a way to identify possible clinical benefits.
Previous studies have shown that TNFAIP8L1 plays a role in tumorigenesis and this
current study asking what pathways it was involved with and through which protein
interactions has revealed a large list of interactors to be validated and further studied. The
importance of elucidating the function of TNFAIP8L1 lies in its importance as a tumor
suppressor, as it could lead to new avenues of study and eventually target specific
treatments for cancer.

41

REFERENCES

American Cancer Society. (2016). Summary of the ACS Guidelines on Nutrition and
Physical Activity. Retrieved from https://www.cancer.org/healthy/eat-healthy-getactive/acs-guidelines-nutrition-physical-activity-cancer-prevention/summary.html
American Cancer Society. (2018a). Economic Impact of Cancer. Retrieved from
https://www.cancer.org/cancer/cancer-basics/economic-impact-of-cancer.html
American Cancer Society. (2018b). Key Statistics for Small Cell Lung Cancer. Retrieved
from https://www.cancer.org/cancer/small-cell-lung-cancer/about/key-statistics.html
American Type Culture Collection. (2016). NCI-H1299 (ATCC® CRL-5803TM).
Retrieved from https://www.atcc.org/en/Products/All/CRL-5803.aspx
Breci, L. (2017). Mass Spec - Chemistry LibreTexts. Retrieved from
https://chem.libretexts.org/Core/Analytical_Chemistry/Instrumental_Analysis/Mass
_Spectrometry/Mass_Spec
Cancer Statistics - National Cancer Institute. (2017). Retrieved from
https://www.cancer.gov/about-cancer/understanding/statistics
Cao, X., Zhang, L., Shi, Y., Sun, Y., Dai, S., Guo, C., … Zhang, L. (2013). Human tumor
necrosis factor (TNF)-alpha-induced protein 8-like 2 suppresses hepatocellular
carcinoma metastasis through inhibiting Rac1. Molecular Cancer, 12(1).
https://doi.org/10.1186/1476-4598-12-149
Cell Culture Basics Handbook. (2016). ThermoFisher Scientific. Retrieved from
https://www.thermofisher.com/content/dam/LifeTech/global/lifesciences/CellCultureandTransfection/pdfs/Gibco-Cell-Culture-Basics-HandbookGlobal.pdf
Center for Disease Control and Prevention. (2017). What Are the Risk Factors for Lung
Cancer? Retrieved from
https://www.cdc.gov/cancer/lung/basic_info/risk_factors.htm
Center for Disease Control and Prevention. (2018). How to Prevent Cancer or Find It
Early. Retrieved from https://www.cdc.gov/cancer/dcpc/prevention/index.htm
Chambost, H., Van Baren, N., Brasseur, F., Godelaine, D., Xerri, L., Landi, S. J., …
Olive, D. (2000). Expression of gene MAGE-A4 in Reed-Sternberg cells. Blood,
95(11), 3530–3533. Retrieved from
http://www.bloodjournal.org/content/95/11/3530.abstract
Chatr-Aryamontri, A., Oughtred, R., Boucher, L., Rust, J., Chang, C., Kolas, N. K., …
Tyers, M. (2017). The BioGRID interaction database: 2017 update. Nucleic Acids
Research, 45(D1), D369–D379. https://doi.org/10.1093/nar/gkw1102
Chen, L., Yang, X., Yang, X., Fan, K., Xiao, P., Zhang, J., & Wang, X. (2016).
Association between the expression levels of tumor necrosis factor-α-induced
protein 8 and the prognosis of patients with gastric adenocarcinoma. Experimental
and Therapeutic Medicine, 12(1), 238–244. https://doi.org/10.3892/etm.2016.3327
42

Cheng, Y., Yu, P., Duan, X., Liu, C., Xu, S., Chen, Y., … Tao, Z. (2015). Genome-wide
analysis of androgen receptor binding sites in prostate cancer cells. Experimental
and Therapeutic Medicine, 9(6), 2319–2324. https://doi.org/10.3892/etm.2015.2406
Cottrell, J. S. (2011). Protein identification using MS/MS data. Journal of Proteomics.
https://doi.org/10.1016/j.jprot.2011.05.014
Cui, J., Hao, C., Zhang, W., Shao, J., Zhang, N., Zhang, G., & Liu, S. (2015). Identical
Expression Profiling of Human and Murine TIPE3 Protein Reveals Links to Its
Functions. Journal of Histochemistry and Cytochemistry, 63(3), 206–216.
https://doi.org/10.1369/0022155414564871
Cui, J., Zhang, G., Hao, C., Wang, Y., Lou, Y., Zhang, W., … Liu, S. (2011). The
expression of TIPE1 in murine tissues and human cell lines. Molecular Immunology,
48(12–13), 1548–1555. https://doi.org/10.1016/j.molimm.2011.04.023
Dammeyer, T., & Schobert, M. (2010). Interactomics. In Handbook of Hydrocarbon and
Lipid Microbiology (pp. 4407–4428). Berlin, Heidelberg: Springer Berlin
Heidelberg. https://doi.org/10.1007/978-3-540-77587-4_345
DeBruyne, J. P., Weaver, D. R., & Reppert, S. M. (2007). CLOCK and NPAS2 have
overlapping roles in the suprachiasmatic circadian clock. Nature Neuroscience,
10(5), 543–545. https://doi.org/10.1038/nn1884
Deng, B., Feng, Y., & Deng, B. (2015). TIPE2 Mediates the Suppressive Effects of
Shikonin on MMP13 in Osteosarcoma Cells. Cellular Physiology and
Biochemistry : International Journal of Experimental Cellular Physiology,
Biochemistry, and Pharmacology, 37(6), 2434–2443.
https://doi.org/10.1159/000438596
Edmondson, R., Broglie, J. J., Adcock, A. F., & Yang, L. (2014). Three-Dimensional
Cell Culture Systems and Their Applications in Drug Discovery and Cell-Based
Biosensors. ASSAY and Drug Development Technologies, 12(4), 207–218.
https://doi.org/10.1089/adt.2014.573
Eisele, L., Klein-Hitpass, L., Chatzimanolis, N., Opalka, B., Boes, T., Seeber, S., …
Flasshove, M. (2007). Differential expression of drug-resistance-related genes
between sensitive and resistant blasts in acute myeloid leukemia. Acta
Haematologica, 117(1), 8–15. https://doi.org/10.1159/000096854
Engel, M. (2014). How the circadian clock may affect cancer. Retrieved from
https://www.fredhutch.org/en/news/center-news/2014/05/Cancer-and-circadianclock.html
Fang, F. C., & Casadevall, A. (2011). Reductionistic and holistic science. Infection and
Immunity, 79(4), 1401–1404. https://doi.org/10.1128/IAI.01343-10
Fayngerts, S. A., Wu, J., Oxley, C. L., Liu, X., Vourekas, A., Cathopoulis, T., … Chen,
Y. H. (2014a). TIPE3 is the transfer protein of lipid second messengers that promote
cancer. Cancer Cell, 26(4), 465–478. https://doi.org/10.1016/j.ccr.2014.07.025
Fayngerts, S. A., Wu, J., Oxley, C. L., Liu, X., Vourekas, A., Cathopoulis, T., … Chen,
Y. H. (2014b). TIPE3 is the transfer protein of lipid second messengers that promote
cancer. Cancer Cell, 26(4), 465–478. https://doi.org/10.1016/j.ccr.2014.07.025
43

Free, R. B., Hazelwood, L. A., & Sibley, D. R. (2009). Identifying novel protein-protein
interactions using co-immunoprecipitation and mass spectroscopy. Current
Protocols in Neuroscience. https://doi.org/10.1002/0471142301.ns0528s46
Giovanella, B. C., Yim, S. O., Stehlin, J. S., & Williams, L. J. (1972). Development of
invasive tumors in the “nude” mouse after injection of cultured human melanoma
cells. Journal of the National Cancer Institute, 48(5), 1531–1533. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/5030962
Ha, J. Y., Kim, J. S., Kang, Y. H., Bok, E., Kim, Y. S., & Son, J. H. (2014). Tnfaip8
l1/Oxi-?? binds to FBXW5, increasing autophagy through activation of TSC2 in a
Parkinson’s disease model. Journal of Neurochemistry, 129(3), 527–538.
https://doi.org/10.1111/jnc.12643
Hamosh, A., Scott, A. F., Amberger, J., Valle, D., & McKusick, V. A. (2000). Online
Mendelian Inheritance in Man (OMIM). Human Mutation, 15(1), 57–61.
https://doi.org/10.1002/(SICI)1098-1004(200001)15:1<57::AIDHUMU12>3.0.CO;2-G
Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100(1), 57–70.
https://doi.org/10.1007/s00262-010-0968-0
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell.
https://doi.org/10.1016/j.cell.2011.02.013
Harvard School of Public Health. (2015). WHO report says eating processed meat is
carcinogenic: Understanding the findings. Retrieved from
https://www.hsph.harvard.edu/nutritionsource/2015/11/03/report-says-eatingprocessed-meat-is-carcinogenic-understanding-the-findings/
Kumar, D., Gokhale, P., Broustas, C., Chakravarty, D., Ahmad, I., & Kasid, U. (2004).
Expression of SCC-S2, an antiapoptotic molecule, correlates with enhanced
proliferation and tumorigenicity of MDA-MB 435 cells. Oncogene, 23(2), 612–616.
https://doi.org/10.1038/sj.onc.1207123
Landgraf, D., Wang, L. L., Diemer, T., & Welsh, D. K. (2016). NPAS2 Compensates for
Loss of CLOCK in Peripheral Circadian Oscillators. PLoS Genetics, 12(2).
https://doi.org/10.1371/journal.pgen.1005882
Li, Y., Li, X., Liu, G., Sun, R., Wang, L., Wang, J., & Wang, H. (2015). Downregulated
TIPE2 is associated with poor prognosis and promotes cell proliferation in nonsmall cell lung cancer. Biochemical and Biophysical Research Communications,
457(1), 43–49. https://doi.org/10.1016/j.bbrc.2014.12.080
Li, Z., Wang, Y., Zhang, M., Xu, P., Huang, H., Wu, D., & Meng, A. (2012). The Amotl2
Gene Inhibits Wnt/β-Catenin Signaling and Regulates Embryonic Development in
Zebrafish. The Journal of Biological Chemistry, 287(16), 13005–13015.
https://doi.org/10.1074/jbc.M112.347419
Liu, K., Qin, C.-K., Wang, Z.-Y., Liu, S.-X., Cui, X.-P., & Zhang, D.-Y. (2012).
Expression of tumor necrosis factor-alpha-induced protein 8 in pancreas tissues and
its correlation with epithelial growth factor receptor levels. Asian Pacific Journal of
Cancer Prevention : APJCP, 13(3), 847–850. Retrieved from
44

http://www.ncbi.nlm.nih.gov/pubmed/22631659
Lou, Y., & Liu, S. (2011). The TIPE (TNFAIP8) family in inflammation, immunity, and
cancer. Molecular Immunology. https://doi.org/10.1016/j.molimm.2011.08.006
Lowe, J. M., Nguyen, T. A., Grimm, S. A., Gabor, K. A., Peddada, S. D., Li, L., …
Fessler, M. B. (2017). The novel p53 target TNFAIP8 variant 2 is increased in
cancer and offsets p53-dependent tumor suppression. Cell Death and
Differentiation, 24(1), 181–191. https://doi.org/10.1038/cdd.2016.130
Mollica, M., Nemeth, L., Newman, S. D., & Mueller, M. (2015). Quality of Life in
African American Breast Cancer Survivors An Integrative Literature Review.
CANCER NURSING, 38(3), 194–204.
https://doi.org/10.1097/NCC.0000000000000160
Moresco, J. J., Carvalho, P. C., & Yates, J. R. (2010). Identifying components of protein
complexes in C. elegans using co-immunoprecipitation and mass spectrometry.
Journal of Proteomics. https://doi.org/10.1016/j.jprot.2010.05.008
National Cancer Institute. (2015). What is Cancer? Retrieved from
https://www.cancer.gov/about-cancer/understanding/what-is-cancer
National Cancer Institute. (2017). Types of Cancer Treatment. Retrieved from
https://www.cancer.gov/about-cancer/treatment/types
National Institute of Health. (2013). RePORT Cancer. Retrieved from
https://report.nih.gov/nihfactsheets/ViewFactSheet.aspx?csid=75
Peng, Y., Zhao, Q., Zhang, H., Han, B., Liu, S., Han, M., & Liu, S. (2016). TIPE2, a
negative regulator of TLR signaling, regulates p27 through IRF4-induced signaling.
Oncology Reports, 35(4), 2480–2486. https://doi.org/10.3892/or.2016.4562
Personalized Medicine. (n.d.). Retrieved from http://mayoresearch.mayo.edu/center-forindividualized-medicine/personalized-medicine.asp
Porturas, T. P., Sun, H., Buchlis, G., Lou, Y., Liang, X., Cathopoulis, T., … Chen, Y. H.
(2015). Crucial Roles of TNFAIP8 Protein in Regulating Apoptosis and Listeria
Infection. The Journal of Immunology, 194(12), 5743–5750.
https://doi.org/10.4049/jimmunol.1401987
Rual, J.-F., Venkatesan, K., Hao, T., Hirozane-Kishikawa, T., Dricot, A., Li, N., …
Vidal, M. (2005). Towards a proteome-scale map of the human protein–protein
interaction network. Nature, 437(7062), 1173–1178.
https://doi.org/10.1038/nature04209
Siegel, R. L., Miller, K. D., & Jemal, A. (2017). Cancer statistics, 2017. CA: A Cancer
Journal for Clinicians, 67(1), 7–30. https://doi.org/10.3322/caac.21387
Sullivan, C., Lage, C. R., Yoder, J. A., Postlethwait, J. H., & Kim, C. H. (2017).
Evolutionary divergence of the vertebrate TNFAIP8 gene family: Applying the
spotted gar orthology bridge to understand ohnolog loss in teleosts. PLoS ONE,
12(6). https://doi.org/10.1371/journal.pone.0179517
Wang, Q. J., Knezetic, J. A., Schally, A. V., Pour, P. M., & Adrian, T. E. (1996).
Bombesin may stimulate proliferation of human pancreatic cancer cells through an
45

autocrine pathway. International Journal of Cancer, 68(4), 528–534.
https://doi.org/10.1002/(SICI)1097-0215(19961115)68:4<528::AIDIJC20>3.0.CO;2-#
World Health Organization. (2018). Cancer Fact Sheet. Retrieved from
http://www.who.int/mediacentre/factsheets/fs297/en/
Wu, X., Ma, Y., Cheng, J., Li, X., Zheng, H., Jiang, L., & Zhou, R. (2017). TIPE1
function as a prognosis predictor and negative regulator of lung cancer. Oncotarget,
8(45), 78496–78506. https://doi.org/10.18632/oncotarget.19655
Xing, B., & Ren, C. (2016). Tumor-suppressive miR-99a inhibits cell proliferation via
targeting of TNFAIP8 in osteosarcoma cells. American Journal of Translational
Research, 8(2), 1082–1090. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/27158394
Zhang, X., Wang, J., Fan, C., Li, H., Sun, H., Gong, S., … Shi, Y. (2009). Crystal
structure of TIPE2 provides insights into immune homeostasis. Nature Structural
and Molecular Biology, 16(1), 89–90. https://doi.org/10.1038/nsmb.1522
Zhang, Z., Liang, X., Gao, L., Ma, H., Liu, X., Pan, Y., … Ma, C. (2015). TIPE1 induces
apoptosis by negatively regulating Rac1 activation in hepatocellular carcinoma cells.
Oncogene, 34(20), 2566–2574. https://doi.org/10.1038/onc.2014.208
Zhang, Z., Qi, H., Hou, S., & Jin, X. (2013). TIPE2 mRNA overexpression correlates
with TNM staging in renal cell carcinoma tissues. Oncology Letters, 6(2), 571–575.
https://doi.org/10.3892/ol.2013.1388

46

APPENDIX A

Supplementary Data
B a it + P r e y
VP16 + GAL4
V P 1 6 -M y o D + G A L 4 -Id
V P 1 6 -T N F A IP 8 L 1 + G A L 4
V P 1 6 -T N F A IP 8 L 1 + G A L 4 -T N F A IP 8 L 1
V P 1 6 -T N F A IP 8 L 1 + G A L 4 -D V L 3
V P 1 6 -T N F A IP 8 L 1 + G A L 4 -F B X W 5
V P 1 6 + G A L 4 -T N F A IP 8 L 1
V P 1 6 -D V L 3 + G A L 4 -T N F A IP 8 L 1
V P 1 6 -F B X W 5 + G A L 4 -T N F A IP 8 L 1
V P 1 6 + G A L 4 -D V L 3
V P 1 6 + G A L 4 -F B X W 5
V P 1 6 -D V L 3 + G A L 4
V P 1 6 -F B X W 5 + G A L 4
0 .0 0

0 .0 1

0 .0 2

0 .0 3

0 .0 4

0 .0 5

0 .1 5

0 .2 0

0 .2 5

R e la t iv e In t e r a c t io n ( F ir e f ly /R e n illa )

Supplementary Figure 1. Results of mammalian two-hybrid assay. The fusion construct
VP16-MyoD + GAL4-Id was used as a positive control. Relative interaction was calculated as
a ratio of firefly luciferase activity to Renilla luciferase activity. Individual points represent
replicates. Controls were performed with 4 replicates each and experimental wells had 8
replicates for each. No significant interaction between experimental constructs was seen in
either experiment.
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ENSG00000116544

34865436

34929585

ENSG00000007174

11598431

11969748

ENSG00000128512

111726110

112206411

ENSG00000088387

98793429

99086625

ENSG00000113719

172834275

172952685

ENSG00000070367

57200507

57269008

ENSG00000174137

1617915

1684302

ENSG00000116120

222570536

222656337

ENSG00000196159

125316399

125492932

ENSG00000007933

171090877

171117819

ENSG00000113327

162000057

162162977

ENSG00000154252

241776825

241804208

ENSG00000276126

241799063

241804208

[Source:HGNC
Symbol;Acc:HGNC:18042]
carboxypeptidase A6
[Source:HGNC
Symbol;Acc:HGNC:17245]
complement C3b/C4b
receptor 1 (Knops blood
group) [Source:HGNC
Symbol;Acc:HGNC:2334]
cytosolic thiouridylase
subunit 1 [Source:HGNC
Symbol;Acc:HGNC:29590]
DDB1 and CUL4 associated
factor 5 [Source:HGNC
Symbol;Acc:HGNC:20224]
deoxycytidine kinase
[Source:HGNC
Symbol;Acc:HGNC:2704]
DEAF1, transcription factor
[Source:HGNC
Symbol;Acc:HGNC:14677]
DExH-box helicase 57
[Source:HGNC
Symbol;Acc:HGNC:20086]
DLG associated protein 3
[Source:HGNC
Symbol;Acc:HGNC:30368]
dynein axonemal heavy
chain 9 [Source:HGNC
Symbol;Acc:HGNC:2953]
dedicator of cytokinesis 4
[Source:HGNC
Symbol;Acc:HGNC:19192]
dedicator of cytokinesis 9
[Source:HGNC
Symbol;Acc:HGNC:14132]
endoplasmic reticulum-golgi
intermediate compartment 1
[Source:HGNC
Symbol;Acc:HGNC:29205]
exocyst complex component
5 [Source:HGNC
Symbol;Acc:HGNC:10696]
family with sequence
similarity 53 member A
[Source:HGNC
Symbol;Acc:HGNC:31860]
phenylalanyl-tRNA
synthetase beta subunit
[Source:HGNC
Symbol;Acc:HGNC:17800]
FAT atypical cadherin 4
[Source:HGNC
Symbol;Acc:HGNC:23109]
flavin containing
monooxygenase 3
[Source:HGNC
Symbol;Acc:HGNC:3771]
gamma-aminobutyric acid
type A receptor gamma2
subunit [Source:HGNC
Symbol;Acc:HGNC:4087]
galactose-3-Osulfotransferase 2
[Source:HGNC
Symbol;Acc:HGNC:24869]
galactose-3-Osulfotransferase 2
[Source:HGNC
Symbol;Acc:HGNC:24869]
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8

CPA6

1

CR1

19

CTU1

14

DCAF5

4

DCK

11

DEAF1

2

DHX57

1

DLGAP3

17

DNAH9

7

DOCK4

13

DOCK9

5

ERGIC1

14

EXOC5

4

FAM53A

2

FARSB

4

FAT4

1

FMO3

5

GABRG2

2

GAL3ST2

CHR_HSCHR2_3_CTG15

GAL3ST2

ENSG00000155511

153489615

153813869

ENSG00000120251

157204182

157366075

ENSG00000125675

123184153

123490915

ENSG00000152578

105609994

105982092

ENSG00000187166

48328980

48330279

ENSG00000246705

14774383

14778002

ENSG00000105968

44826791

44848083

ENSG00000188486

119093854

119095467

ENSG00000164032

99948086

99950388

ENSG00000164508

25726132

25726527

ENSG00000278463

26033176

26033568

ENSG00000180573

26124145

26139116

ENSG00000196866

26198851

26199243

ENSG00000277075

26216975

26217483

ENSG00000196787

27133042

27135291

ENSG00000274997

27147129

27147515

ENSG00000196747

27808199

27808701

ENSG00000276368

27814354

27814740

ENSG00000275221

27837947

27838339

ENSG00000276903

27865355

27865747

ENSG00000278677

27892757

27893149

ENSG00000203812

149842188

149842736

glutamate ionotropic
receptor AMPA type subunit
1 [Source:HGNC
Symbol;Acc:HGNC:4571]
glutamate ionotropic
receptor AMPA type subunit
2 [Source:HGNC
Symbol;Acc:HGNC:4572]
glutamate ionotropic
receptor AMPA type subunit
3 [Source:HGNC
Symbol;Acc:HGNC:4573]
glutamate ionotropic
receptor AMPA type subunit
4 [Source:HGNC
Symbol;Acc:HGNC:4574]
H1 histone family member
N, testis specific
[Source:HGNC
Symbol;Acc:HGNC:24893]
H2A histone family member
J [Source:HGNC
Symbol;Acc:HGNC:14456]
H2A histone family member
V [Source:HGNC
Symbol;Acc:HGNC:20664]
H2A histone family member
X [Source:HGNC
Symbol;Acc:HGNC:4739]
H2A histone family member
Z [Source:HGNC
Symbol;Acc:HGNC:4741]
histone cluster 1 H2A family
member a [Source:HGNC
Symbol;Acc:HGNC:18729]
histone cluster 1 H2A family
member b [Source:HGNC
Symbol;Acc:HGNC:4734]
histone cluster 1 H2A family
member c [Source:HGNC
Symbol;Acc:HGNC:4733]
histone cluster 1 H2A family
member d [Source:HGNC
Symbol;Acc:HGNC:4729]
histone cluster 1 H2A family
member e [Source:HGNC
Symbol;Acc:HGNC:4724]
histone cluster 1 H2A family
member g [Source:HGNC
Symbol;Acc:HGNC:4737]
histone cluster 1 H2A family
member h [Source:HGNC
Symbol;Acc:HGNC:13671]
histone cluster 1 H2A family
member i [Source:HGNC
Symbol;Acc:HGNC:4725]
histone cluster 1 H2A family
member j [Source:HGNC
Symbol;Acc:HGNC:4727]
histone cluster 1 H2A family
member k [Source:HGNC
Symbol;Acc:HGNC:4726]
histone cluster 1 H2A family
member l [Source:HGNC
Symbol;Acc:HGNC:4730]
histone cluster 1 H2A family
member m [Source:HGNC
Symbol;Acc:HGNC:4735]
histone cluster 2 H2A family
member a3 [Source:HGNC
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5

GRIA1

4

GRIA2

X

GRIA3

11

GRIA4

12

H1FNT

12

H2AFJ

7

H2AFV

11

H2AFX

4

H2AFZ

6

HIST1H2AA

6

HIST1H2AB

6

HIST1H2AC

6

HIST1H2AD

6

HIST1H2AE

6

HIST1H2AG

6

HIST1H2AH

6

HIST1H2AI

6

HIST1H2AJ

6

HIST1H2AK

6

HIST1H2AL

6

HIST1H2AM

1

HIST2H2AA3

ENSG00000272196

149851061

149851624

ENSG00000184260

149886975

149887364

ENSG00000181218

228456979

228457873

ENSG00000135486

54280193

54287088

ENSG00000163913

129440036

129520507

ENSG00000270505

22160431

22160868

ENSG00000270467

33802764

33803217

ENSG00000149503

62123973

62153163

ENSG00000188487

15112424

15247208

ENSG00000168264

234604269

234609525

ENSG00000276289

7816675

7829926

ENSG00000197705

32672671

32773062

ENSG00000055609

152134922

152436005

ENSG00000135480

52232520

52252186

ENSG00000141068

27456470

27626438

ENSG00000133067

202193901

202319781

ENSG00000167210

46476972

46657220

ENSG00000147381

151912509

151925170

ENSG00000196547

90902218

90922584

ENSG00000168906

85539165

85545280

Symbol;Acc:HGNC:4736]
histone cluster 2 H2A family
member a4 [Source:HGNC
Symbol;Acc:HGNC:29668]
histone cluster 2 H2A family
member c [Source:HGNC
Symbol;Acc:HGNC:4738]
histone cluster 3 H2A
[Source:HGNC
Symbol;Acc:HGNC:20507]
heterogeneous nuclear
ribonucleoprotein A1
[Source:HGNC
Symbol;Acc:HGNC:5031]
intraflagellar transport 122
[Source:HGNC
Symbol;Acc:HGNC:13556]
immunoglobulin heavy
variable 1/OR15-1 (nonfunctional) [Source:HGNC
Symbol;Acc:HGNC:5563]
immunoglobulin heavy
variable 3/OR16-12 (nonfunctional) [Source:HGNC
Symbol;Acc:HGNC:5636]
inner centromere protein
[Source:HGNC
Symbol;Acc:HGNC:6058]
INSC, spindle orientation
adaptor protein
[Source:HGNC
Symbol;Acc:HGNC:33116]
interferon regulatory factor 2
binding protein 2
[Source:HGNC
Symbol;Acc:HGNC:21729]
potassium voltage-gated
channel subfamily E
regulatory subunit 1B
[Source:HGNC
Symbol;Acc:HGNC:52280]
kelch like family member 14
[Source:HGNC
Symbol;Acc:HGNC:29266]
lysine methyltransferase 2C
[Source:HGNC
Symbol;Acc:HGNC:13726]
keratin 7 [Source:HGNC
Symbol;Acc:HGNC:6445]
kinase suppressor of ras 1
[Source:HGNC
Symbol;Acc:HGNC:6465]
leucine rich repeat
containing G proteincoupled receptor 6
[Source:HGNC
Symbol;Acc:HGNC:19719]
lipoxygenase homology
domains 1 [Source:HGNC
Symbol;Acc:HGNC:26521]
MAGE family member A4
[Source:HGNC
Symbol;Acc:HGNC:6802]
mannosidase alpha class 2A
member 2 [Source:HGNC
Symbol;Acc:HGNC:6825]
methionine
adenosyltransferase 2A
[Source:HGNC
Symbol;Acc:HGNC:6904]
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1

HIST2H2AA4

1

HIST2H2AC

1

HIST3H2A

12

HNRNPA1

3

IFT122

15

IGHV1OR151

16

IGHV3OR1612

11

INCENP

11

INSC

1

IRF2BP2

21

KCNE1B

18

KLHL14

7

KMT2C

12

KRT7

17

KSR1

1

LGR6

18

LOXHD1

X

MAGEA4

15

MAN2A2

2

MAT2A

ENSG00000258839

89912119

89920977

ENSG00000183019

7676628

7679826

ENSG00000175221

867630

893218

ENSG00000176624

51174550

51218304

ENSG00000135517

56449502

56469166

ENSG00000171843

20341665

20622543

ENSG00000074071

1771890

1773155

ENSG00000197535

52307283

52529050

ENSG00000066248

232878686

233013272

ENSG00000055044

202265716

202303666

ENSG00000170485

100820152

100996829

ENSG00000148200

124517275

124771310

ENSG00000122126

129539849

129592561

ENSG00000167332

4680171

4697854

ENSG00000172464

56641466

56642471

ENSG00000181752

56159394

56160317

ENSG00000187950

29412474

29497686

ENSG00000110811

6828410

6839851

ENSG00000163110

94451857

94668227

ENSG00000185238

20387530

20509294

ENSG00000135406

49293252

49298686

melanocortin 1 receptor
[Source:HGNC
Symbol;Acc:HGNC:6929]
mast cell expressed
membrane protein 1
[Source:HGNC
Symbol;Acc:HGNC:27291]
mediator complex subunit 16
[Source:HGNC
Symbol;Acc:HGNC:17556]
mex-3 RNA binding family
member C [Source:HGNC
Symbol;Acc:HGNC:28040]
major intrinsic protein of
lens fiber [Source:HGNC
Symbol;Acc:HGNC:7103]
MLLT3, super elongation
complex subunit
[Source:HGNC
Symbol;Acc:HGNC:7136]
mitochondrial ribosomal
protein S34 [Source:HGNC
Symbol;Acc:HGNC:16618]
myosin VA [Source:HGNC
Symbol;Acc:HGNC:7602]
neuronal guanine nucleotide
exchange factor
[Source:HGNC
Symbol;Acc:HGNC:7807]
NOP58 ribonucleoprotein
[Source:HGNC
Symbol;Acc:HGNC:29926]
neuronal PAS domain
protein 2 [Source:HGNC
Symbol;Acc:HGNC:7895]
nuclear receptor subfamily 6
group A member 1
[Source:HGNC
Symbol;Acc:HGNC:7985]
OCRL, inositol
polyphosphate-5phosphatase [Source:HGNC
Symbol;Acc:HGNC:8108]
olfactory receptor family 51
subfamily E member 2
[Source:HGNC
Symbol;Acc:HGNC:15195]
olfactory receptor family 5
subfamily AP member 2
[Source:HGNC
Symbol;Acc:HGNC:15258]
olfactory receptor family 8
subfamily K member 5
[Source:HGNC
Symbol;Acc:HGNC:15315]
ovochymase 1
[Source:HGNC
Symbol;Acc:HGNC:23080]
prolyl 3-hydroxylase 3
[Source:HGNC
Symbol;Acc:HGNC:19318]
PDZ and LIM domain 5
[Source:HGNC
Symbol;Acc:HGNC:17468]
protein arginine
methyltransferase 3
[Source:HGNC
Symbol;Acc:HGNC:30163]
peripherin [Source:HGNC
Symbol;Acc:HGNC:9461]
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16

MC1R

19

MCEMP1

19

MED16

18

MEX3C

12

MIP

9

MLLT3

16

MRPS34

15

MYO5A

2

NGEF

2

NOP58

2

NPAS2

9

NR6A1

X

OCRL

11

OR51E2

11

OR5AP2

11

OR8K5

12

OVCH1

12

P3H3

4

PDLIM5

11

PRMT3

12

PRPH

ENSG00000100804

23016543

23035230

ENSG00000108469

75626845

75667189

ENSG00000143344

183636085

183928531

ENSG00000080345

151409883

151508013

ENSG00000137522

71928701

71997597

ENSG00000198863

42980565

42993690

ENSG00000196218

38433699

38587564

ENSG00000137872

47184101

47774223

ENSG00000163904

185582496

185633551

ENSG00000140264

43777087

43802589

ENSG00000170364

4303304

4317567

ENSG00000100014

24270817

24417740

ENSG00000138600

50702266

50765808

ENSG00000159433

42575659

42720981

ENSG00000164506

147204425

147390476

ENSG00000144455

3700814

4467281

ENSG00000156787

123041968

123152153

ENSG00000176946

241584405

241637449

ENSG00000115705

1374223

1543711

ENSG00000277603

1372594

1540021

ENSG00000128881

42738734

42920809

ENSG00000177398

42062959

42143453

proteasome subunit beta 5
[Source:HGNC
Symbol;Acc:HGNC:9542]
RecQ like helicase 5
[Source:HGNC
Symbol;Acc:HGNC:9950]
ral guanine nucleotide
dissociation stimulator like 1
[Source:HGNC
Symbol;Acc:HGNC:30281]
replication timing regulatory
factor 1 [Source:HGNC
Symbol;Acc:HGNC:23207]
ring finger protein 121
[Source:HGNC
Symbol;Acc:HGNC:21070]
RUN domain containing 1
[Source:HGNC
Symbol;Acc:HGNC:25418]
ryanodine receptor 1
[Source:HGNC
Symbol;Acc:HGNC:10483]
semaphorin 6D
[Source:HGNC
Symbol;Acc:HGNC:16770]
SUMO1/sentrin/SMT3
specific peptidase 2
[Source:HGNC
Symbol;Acc:HGNC:23116]
small EDRK-rich factor 2
[Source:HGNC
Symbol;Acc:HGNC:10757]
SET domain and mariner
transposase fusion gene
[Source:HGNC
Symbol;Acc:HGNC:10762]
sperm antigen with calponin
homology and coiled-coil
domains 1 like
[Source:HGNC
Symbol;Acc:HGNC:29022]
signal peptide peptidase like
2A [Source:HGNC
Symbol;Acc:HGNC:30227]
StAR related lipid transfer
domain containing 9
[Source:HGNC
Symbol;Acc:HGNC:19162]
syntaxin binding protein 5
[Source:HGNC
Symbol;Acc:HGNC:19665]
sulfatase modifying factor 1
[Source:HGNC
Symbol;Acc:HGNC:20376]
TBC1 domain family
member 31 [Source:HGNC
Symbol;Acc:HGNC:30888]
THAP domain containing 4
[Source:HGNC
Symbol;Acc:HGNC:23187]
thyroid peroxidase
[Source:HGNC
Symbol;Acc:HGNC:12015]
thyroid peroxidase
[Source:HGNC
Symbol;Acc:HGNC:12015]
tau tubulin kinase 2
[Source:HGNC
Symbol;Acc:HGNC:19141]
uromodulin like 1
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14

PSMB5

17

RECQL5

1

RGL1

2

RIF1

11

RNF121

17

RUNDC1

19

RYR1

15

SEMA6D

3

SENP2

15

SERF2

3

SETMAR

22

SPECC1L

15

SPPL2A

15

STARD9

6

STXBP5

3

SUMF1

8

TBC1D31

2

THAP4

2

TPO

CHR_HSCHR2_4_CTG1

TPO

15

TTBK2

21

UMODL1

ENSG00000109189

52590972

52659335

ENSG00000143952

63892146

64019072

ENSG00000167716

1716523

1738599

ENSG00000276021

1716523

1738610

ENSG00000142784

27234516

27308633

ENSG00000241127

39566376

39610320

ENSG00000140836

72782885

73891871

ENSG00000196646

12163064

12189881

ENSG00000267680

44094339

44109886

ENSG00000160094

33256545

33300719

ENSG00000180938

124973298

124979389

ENSG00000188171

20620061

20661596

[Source:HGNC
Symbol;Acc:HGNC:12560]
ubiquitin specific peptidase
46 [Source:HGNC
Symbol;Acc:HGNC:20075]
VPS54, GARP complex
subunit [Source:HGNC
Symbol;Acc:HGNC:18652]
WD repeat domain 81
[Source:HGNC
Symbol;Acc:HGNC:26600]
WD repeat domain 81
[Source:HGNC
Symbol;Acc:HGNC:26600]
WD and tetratricopeptide
repeats 1 [Source:HGNC
Symbol;Acc:HGNC:29175]
Yae1 domain containing 1
[Source:HGNC
Symbol;Acc:HGNC:24857]
zinc finger homeobox 3
[Source:HGNC
Symbol;Acc:HGNC:777]
zinc finger protein 136
[Source:HGNC
Symbol;Acc:HGNC:12920]
zinc finger protein 224
[Source:HGNC
Symbol;Acc:HGNC:13017]
zinc finger protein 362
[Source:HGNC
Symbol;Acc:HGNC:18079]
zinc finger protein 572
[Source:HGNC
Symbol;Acc:HGNC:26758]
zinc finger protein 626
[Source:HGNC
Symbol;Acc:HGNC:30461]

4

USP46

2

VPS54

17

WDR81

CHR_HSCHR17_1_CTG2

WDR81

1

WDTC1

7

YAE1D1

16

ZFHX3

19

ZNF136

19

ZNF224

1

ZNF362

8

ZNF572

19

ZNF626

Supplementary Table 1. Summary of 138 unique genes interactors pulled out in mass
spectrometry.
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